Alector Stock Forecast, Price & News

-0.49 (-1.61 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume932,457 shs
Average Volume993,008 shs
Market Capitalization$2.39 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALEC News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

Alector logo

About Alector

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.82 out of 5 stars

Medical Sector

657th out of 2,218 stocks

Biological Products, Except Diagnostic Industry

92nd out of 213 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Alector (NASDAQ:ALEC) Frequently Asked Questions

Is Alector a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alector stock.
View analyst ratings for Alector
or view top-rated stocks.

What stocks does MarketBeat like better than Alector?

Wall Street analysts have given Alector a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alector wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Alector?

Alector saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 6,180,000 shares, a drop of 16.5% from the June 30th total of 7,400,000 shares. Based on an average daily volume of 1,400,000 shares, the short-interest ratio is presently 4.4 days. Currently, 11.0% of the shares of the stock are short sold.
View Alector's Short Interest

When is Alector's next earnings date?

Alector is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Alector

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) issued its earnings results on Tuesday, May, 4th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.69) by $0.03. The firm earned $4.11 million during the quarter, compared to analysts' expectations of $6.42 million. Alector had a negative trailing twelve-month return on equity of 69.73% and a negative net margin of 1,122.03%.
View Alector's earnings history

How has Alector's stock been impacted by COVID-19 (Coronavirus)?

Alector's stock was trading at $24.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALEC stock has increased by 20.1% and is now trading at $29.94.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ALEC?

6 analysts have issued 1 year price targets for Alector's stock. Their forecasts range from $29.00 to $57.00. On average, they anticipate Alector's stock price to reach $38.29 in the next year. This suggests a possible upside of 27.9% from the stock's current price.
View analysts' price targets for Alector
or view top-rated stocks among Wall Street analysts.

Who are Alector's key executives?

Alector's management team includes the following people:
  • Dr. Tillman Ulf Gerngross, Co-Founder & Chairman (Age 57, Pay $60k)
  • Dr. Arnon Rosenthal, Co-Founder, CEO & Director (Age 65, Pay $566.02k)
  • Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Pres, COO & Interim Chief Bus. Officer (Age 49, Pay $677.76k)
  • Mr. Calvin Yu, VP of Fin. (Age 45, Pay $370.87k) (LinkedIn Profile)
  • Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 53, Pay $568.5k)
  • Dr. Robert S. King, Chief Devel. Officer (Age 58, Pay $556.21k)
  • Mr. Charles Wolfus, VP of Technology & Digital Health
  • Mr. Brian Sander J.D., Ph.D., Gen. Counsel
  • Erica Jefferson, VP of Communications & Public Affairs
  • Ms. Clare Hunt M.B.A., Head of People

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector CEO Arnon Rosenthal on Arnon Rosenthal has an approval rating of 100% among Alector's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Alector's key competitors?

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.

What is Alector's stock symbol?

Alector trades on the NASDAQ under the ticker symbol "ALEC."

How do I buy shares of Alector?

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alector's stock price today?

One share of ALEC stock can currently be purchased for approximately $29.94.

How much money does Alector make?

Alector has a market capitalization of $2.39 billion and generates $21.10 million in revenue each year. The company earns $-190,230,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

How many employees does Alector have?

Alector employs 181 workers across the globe.

What is Alector's official website?

The official website for Alector is

Where are Alector's headquarters?

Alector is headquartered at 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Alector?

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.